About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. To receive additional information on the Company, please visit our website at http://www.favrille.com. Information on our website does not, however, form a part of this press release.
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to the expected closing date for the
financing, Favrille's product candidates, proprietary technologies and
research programs. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause Favrille's
actual results to be materially different from historical results or from
any results expressed or implied by such forward-looking statements. These
factors include, but are not limited to, risks and uncertainties related to
whether the offering will close when expected or at all; progress and
timing of clinical trials for FavId, including difficulties or delays in
development, testing, ma
|SOURCE Favrille, Inc.|
Copyright©2007 PR Newswire.
All rights reserved